Clinical trials: Malignant Ascites
Malignant Ascites, Malignant Pleural Effusion
Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion
In some patients with cancer there are also cancer cells in the abdominal cavity or between the lung membranes. These cancer cells create too much moisture in the abdominal cavity or between the lung membranes.
- Trial name
- NCT01262612
- Testing
- immediate cediranib, Start cediranib after 28 days Best Supportive Care
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Radboud University Medical Center
Peritoneum Cancer, Peritoneum Neoplasm
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Multicentric, international, web-based prospective documentation of the indications and results of Pressurized Aerosol Chemotherapy (so-called PIPAC or PITAC) for treating malignant pleural and peritoneal diseases.
- Conditions
- Peritoneum Cancer, Peritoneum Neoplasm, Pleural Cancer, Pleural Effusion
- Trial name
- PIPACRegis (NCT03210298)
- Testing
- PIPAC
- Where
- 16 sites in Argentina, Australia and 11 more
- Volunteers
- 1,000 people
- Sponsor
- Sabine Rhode
Refractory Malignant Ascites
Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant Ascites
The refractory malignant ascites is a complication of advanced stages of many cancer types. It is characterized clinically by abdominal pressure sensation, shortness of breath and pelvic pain.
- Trial name
- BEVASCITE (NCT02891369)
- Testing
- No intervention. Descriptive study
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Malignant Ascites
At-Home Paracentesis for Cancer-Related Malignant Ascites (Paracentesis)
The goal of this study is to evaluate the change in symptoms for cancer-related malignant ascites who complete an at-home paracentesis procedure.
- Trial name
- Paracentesis (NCT07490626)
- Testing
- At-home Paracentesis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Malignant Ascites
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
The purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.
- Trial name
- NCT00326885
- Testing
- catumaxomab
- Where
- 18 sites in United States
- Volunteers
- 32 people
- Sponsor
- Neovii Biotech
Malignant Peritoneal Effusion, Malignant Ascites
Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases
This is a Phase I, open-label, single-arm, dose-escalation and expansion study designed to evaluate the safety, tolerability, and preliminary antitumor activity of dual-targeting VEGFR1/PD-L1 chimeric antigen receptor (CAR)…
- Conditions
- Malignant Peritoneal Effusion, Malignant Ascites, Serous Cavity Metastatises, Leptomeningeal Metastases
- Trial name
- NCT05477927
- Testing
- Dual-targeting VEGFR1/PD-L1 CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Malignant Ascites
Malignant Ascites Alfapump® Study
ProMAS is a prospective post-marketing, single-arm study to assess performance and safety of the Alfapump® system in the treatment of patients with malignant ascites.
- Trial name
- ProMAS (NCT04076566)
- Testing
- alfapump system
- Where
- United Kingdom
- Sponsor
- Sequana Medical N.V.
Peritoneal Neoplasms, Ascites
Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT
This trial studies efficacy and safety of combination of modulated electro-hyperthermia (mEHT) with Traditional Chinese Medicine (TCM) in treatment of peritoneal carcinomatosis with malignant ascites versus standard chemoinfusion…
- Conditions
- Peritoneal Neoplasms, Ascites, Yang Deficiency, Yin Deficiency
- Trial name
- OTMA-RII (NCT02638051)
- Testing
- Modulated Electro-Hyperthermia (mEHT), TCM Herbal Decoction (Shi Pi), IPCI (CDDP+5FU)
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Galenic Research Institute Ltd
Ovarian Neoplasms, Ascites
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer. Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)…
- Trial name
- NCT00327444
- Testing
- aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 9 sites in United States, Austria and 7 more
- Volunteers
- 58 people
- Sponsor
- Sanofi
Cancer
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005860
- Testing
- floxuridine, leucovorin calcium, oxaliplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Pleural Effusion, Malignant Ascites
Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites
The objective of this study is to compare the efficacy of Endostar/cisplatin with cisplatin alone or Endostar alone in patients with malignant pleural effusion or ascites.
- Trial name
- NCT01327235
- Testing
- Endostar, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 336 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Gastric Cancer, Peritoneal Metastases
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
To evaluate the efficacy and safety of Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion as First-line Treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma…
- Conditions
- Gastric Cancer, Peritoneal Metastases, Ascites, Malignant
- Trial name
- NCT06046963
- Testing
- Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion, Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital
Malignant Ascites
An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites
The purpose of this study is to assess in a controlled prospective setting, the safety of the use of Pleurx catheters and standard therapeutic paracentesis in patients with malignant ascites.
- Trial name
- NCT01077063
- Testing
- paracentesis, Pleurx catheter
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Digestive System Cancer, Malignant Ascites
A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites
To evaluate the tolerance and safety of cinobufacini injection intraperitoneal treatment on digestive system cancer patients with malignant ascites, and propose dosage regimens for future clinical trials.
- Trial name
- NCT02530398
- Testing
- Cinobufacini Injection
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Dongfang Hospital Beijing University of Chinese Medicine
Metastatic Cancer
Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Peritoneal infusion of heated chemotherapy drugs, such as mitomycin, may kill more tumor cells.
- Trial name
- NCT00265863
- Testing
- mitomycin C
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Malignant Pleural Effusion,, Malignant Ascites
Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion
Malignant ascites and pleural effusion are common symptoms in patients with advanced cancer. Currently, the management of malignant ascites and pleural effusion is a considerable clinical challenge.
- Trial name
- NCT01854866
- Testing
- Drug-packaging microparticles
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huazhong University of Science and Technology
Malignant Ascites, Apatinib
A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites
Malignant ascites is a severe complication of many types of human cancer. Animal and clinical analyses have shown that angiogenesis plays a critical role in the formation of malignant ascites.
- Trial name
- NCT03020979
- Testing
- Apatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Liver Cirrhosis, Refractory Ascites
ALFApump System Post Marketing Surveillance Registry
This is a post market surveillance registry to monitor the safety and performance of the ALFApump system.
- Conditions
- Liver Cirrhosis, Refractory Ascites, Malignant Ascites
- Trial name
- 2011-AAR-004 (NCT01532427)
- Where
- 13 sites in Germany, Spain and 2 more
- Volunteers
- 100 people
- Sponsor
- Sequana Medical N.V.
Ascites, Malignant
Quality of Life of Patients Who Have Rocket Indwelling Pleural Catheter Drainage or Repeated Large Volume Paracentesis
Ascites (accumulation of fluid in the abdominal cavity) is a common problem which can lead to distressing symptoms. When caused by cancer, management options are chemotherapy, diuretics and ascitic drainage.
- Trial name
- NCT03550690
- Testing
- Large Volume Paracentesis, Rocket Indwelling Pleural Catheter
- Volunteers
- 20 people
- Sponsor
- Gloucestershire Hospitals NHS Foundation Trust
Chylous Ascites, Abdominal Neoplasm
Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy
The goal of this clinical trial is to assess the effectiveness of oral iohexol in the treatment of postoperative chylous ascites. It will also learn about the safety of oral iohexol.
- Conditions
- Chylous Ascites, Abdominal Neoplasm, Pelvic Neoplasms, Retroperitoneal Lymph Node Metastasis
- Trial name
- NCT06820320
- Testing
- oral iohexol, Lymphangiography and Embolization
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences